Tumour characteristics shifted towards earlier-stage disease, with increased detection of small tumours ≤30 mm (56% to 71%, <i>p</i> < 0.001), fewer muscle-invasive cases (27% to 21%, <i>p</i> = 0.003) and a higher proportion of TaG1-2 tumours (42% to 52%, <i>p</i> = 0.003). This evidence concerns the gene CNTN2 and neoplasm.